SG Americas Securities LLC raised its holdings in shares of FibroGen, Inc (NASDAQ:FGEN) by 107.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,006 shares of the biopharmaceutical company’s stock after acquiring an additional 7,259 shares during the period. SG Americas Securities LLC’s holdings in FibroGen were worth $754,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. New York State Common Retirement Fund raised its stake in FibroGen by 24.0% during the 2nd quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock valued at $2,187,000 after acquiring an additional 13,099 shares in the last quarter. FMR LLC raised its stake in FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after acquiring an additional 1,641,423 shares in the last quarter. Prudential Financial Inc. raised its stake in FibroGen by 9.6% during the 2nd quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock valued at $14,496,000 after acquiring an additional 39,430 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in FibroGen by 12.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,284 shares of the biopharmaceutical company’s stock valued at $1,495,000 after acquiring an additional 5,022 shares in the last quarter. Finally, Strs Ohio raised its stake in FibroGen by 15.3% during the 3rd quarter. Strs Ohio now owns 164,900 shares of the biopharmaceutical company’s stock valued at $8,871,000 after acquiring an additional 21,900 shares in the last quarter. 57.42% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently commented on FGEN. Jefferies Group reissued a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research note on Tuesday, September 12th. Mizuho reissued a “hold” rating and issued a $61.00 price objective on shares of FibroGen in a research note on Thursday, November 9th. Stifel Nicolaus reissued a “buy” rating and issued a $80.00 price objective on shares of FibroGen in a research note on Thursday, September 14th. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Citigroup boosted their price objective on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. FibroGen has a consensus rating of “Buy” and an average price target of $65.67.

Shares of FibroGen, Inc (FGEN) opened at $44.45 on Wednesday. FibroGen, Inc has a 12 month low of $19.25 and a 12 month high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.

In related news, Director Gerald Lema bought 3,500 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were bought at an average cost of $46.70 per share, with a total value of $163,450.00. Following the completion of the transaction, the director now directly owns 3,500 shares of the company’s stock, valued at $163,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider K Peony Yu sold 40,000 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.63, for a total value of $2,185,200.00. The disclosure for this sale can be found here. Insiders sold a total of 399,982 shares of company stock worth $21,250,362 in the last three months. Company insiders own 13.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/06/sg-americas-securities-llc-has-754000-position-in-fibrogen-inc-fgen.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.